MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/liv.14280

Медицинская библиотека · Liver international : official journal of the International Association for the Study of the Liver · 2019

Permanent immunosuppression in SLA/LP-positive autoimmune hepatitis is required although overall response and survival are similar.

Zachou Kalliopi, Weiler-Normann Christina, Muratori Luigi, Muratori Paolo, Lohse Ansgar W, Dalekos George N

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND AND AIMS: Antibodies against soluble liver antigen/liver pancreas (anti-SLA/LP) are highly specific for autoimmune hepatitis (AIH) and have been linked with a more severe clinical course of the disease, frequent relapses after treatment withdrawal and worse outcome. To address definitely the clinical significance of anti-SLA/LP, we investigated a large number of anti-SLA/LP-positive and -negative patients followed in three referral centres.

METHODS

Prospectively collected data from 89 anti-SLA/LP-positive AIH patients (29 from Hamburg-Germany, 20 from Bologna-Italy and 40 from Larissa-Greece) were analysed retrospectively. Age- and sex-matched anti-SLA/LP-negative patients served as disease controls (n = 230; 1:2.5 ratio).

RESULTS

In respect to baseline characteristics, anti-SLA/LP-positive patients were more frequently asymptomatic compared to anti-SLA/LP-negative (P < .05). However, anti-SLA/LP-positive patients did not differ from anti-SLA/LP-negative in terms of the overall response to treatment, disease progression and survival even though, they were less likely to achieve corticosteroid withdrawal (P < .05), needed longer treatment duration to achieve first complete response (P < .001) and relapsed more frequently after treatment withdrawal compared to anti-SLA/LP-negative patients (P = <.001).

CONCLUSIONS

We showed that anti-SLA/LP antibodies do not characterize a group of AIH patients with distinct features and cannot identify patients with a more severe form of the disease or worse survival. Most importantly, however, anti-SLA/LP-positive patients appear to require lifelong immunosuppression as they are less likely to achieve the cessation of corticosteroids and present higher relapse rates after treatment withdrawal. Therefore, close long-term monitoring should be advised in all anti-SLA/LP-positive patients after withdrawal of immunosuppressive treatment.

Для цитирования: Zachou Kalliopi, Weiler-Normann Christina, Muratori Luigi, Muratori Paolo, Lohse Ansgar W, Dalekos George N. Permanent immunosuppression in SLA/LP-positive autoimmune hepatitis is required although overall response and survival are similar.. Liver international : official journal of the International Association for the Study of the Liver. 2019. DOI: 10.1111/liv.14280.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.